U.S. markets open in 8 hours 10 minutes

Qiagen N.V. (QGEN)

NYSE - NYSE Delayed Price. Currency in USD
43.49-0.07 (-0.16%)
At close: 04:00PM EST
43.49 +0.00 (+0.00%)
After hours: 04:09PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close43.56
Bid0.00 x 900
Ask0.00 x 800
Day's Range43.24 - 43.53
52 Week Range34.74 - 47.70
Avg. Volume1,329,045
Market Cap9.626B
Beta (5Y Monthly)0.43
PE Ratio (TTM)28.42
EPS (TTM)1.53
Earnings DateMay 01, 2024 - May 06, 2024
Forward Dividend & Yield1.28 (2.94%)
Ex-Dividend DateJan 30, 2024
1y Target Est51.15
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
14% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for QGEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Qiagen N.V.
    Analyst Report: Qiagen N.V.Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
    Fair Value
    Economic Moat
    21 days agoMorningstar
View more
  • GlobeNewswire

    QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

    QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven drug discovery // AI-driven insights complement human-curated QIAGEN Biomedical KB-HD and help identify novel relationships between diseases, biological pathways and molecular interactions that may be missed by traditional methods // Workflow cuts down on hypothesis testing time and speeds up the identification of promising therapeutic avenues w

  • GlobeNewswire

    QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification

    Additional ecofriendly QIAwave kits for DNA and RNA extraction receive ACT Label due to greatly improved Environmental Impact Factor compared to standard kits // QIAGEN’s Sample technologies R&D lab in Germany achieves My Green Lab Platinum certification, roadmap adopted for further certifications at site //Strong commitment to further reduce plastic packaging and greenhouse gas emissions as part of comprehensive ESG strategy focused on improving QIAGEN’s impact on societyVenlo, the Netherlands,

  • Zacks

    QIAGEN (QGEN) Earns Notable Recognitions in Sustainability

    QIAGEN (QGEN) achieves the ACT Label for new eco-friendly QIAwave products and the first My Green Lab Platinum certification.